Use of packing strip as a holographic data carrier
AssigneeCiba Specialty Chemicals Corporation
InventorsPaul Adriaan Van Der Schaaf, Heinz Wolleb, Annemarie Wolleb, Claudia Marcolli, Martin Szelagiewicz, Andreas Burkhard, Beat Freiermuth
Life of this patent
Estimating the term…
Abstract
Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomer of fluvastatin were found, referred to hereinafter as polymorphic Forms A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
Claims20
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 22.6 (w), 7.9 (w), 7.4 (s), 6.9 (m), 6.2 (m), 5.52 (w), 5.04 (vs), 4.85 (vs), 4.72 (w), 4.46 (m), 4.30 (s), 4.09 (s), 3.93 (m), 3.73 (vw), 3.67 (w), 3.52 (w), 3.45 (w), 3.35 (w), 3.21 (m) 3.02 (w), 2.86 (w), 2.73 (vw), 2.64 (vw), 2.50 (vw), 2.44 (w), 2.35 (vw), 2.28 (vw),
- wherein (vs)=very strong intensity;
- (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which has characteristic Raman bands, expressed in wave number (cm−1):
- 3067 (m), 2992 (w), 2945 (m), 2914 (m), 1656 (vs), 1602 (s), 1570 (m), 1537 (s), 1500 (s), 1458 (s), 1421 (m), 1387 (m), 1360 (w), 1339 (m), 1299 (m), 1237 (w), 1209 (m), 1159 (w), 1141 (w), 1118 (w), 1072 (w), 1023 (w), 969 (w), 943 (w), 917 (w), 891 (w), 847 (w), 815 (m), 775 (w), 757 (w), 719 (w), 695 (w), 633 (w), 605 (w), 565 (w), 532 (w), 423 (w), 391 (w), 351 (w), 278 (w), 191 (m);
- wherein (vs)=very strong intensity;
- (s)=strong intensity;
- (m)=medium intensity;
- and (w)=weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 24.2 (m), 12.4 (vw), 9.1 (vw), 8.2 (s), 7.1 (m), 6.0 (vw), 5.54 (w), 5.17 (vw), 4.90 (m), 4.73 (m), 4.08 (m), 3.48 (vw), 2.98 (vw),
- wherein (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 25.2 (w), 12.1 (vw), 8.6 (m), 8.1 (m), 7.1 (w), 6.4 (vw), 5.99 (w), 5.69 (vw), 5.57 (w), 5.22 (w), 4.93 (s), 4.78 (s), 4.50 (w), 4.30 (vw), 4.12 (s), 3.80 (m), 3.71 (vw), 3.46 (w), 3.34 (w), 3.23 (vw), 2.97 (w),
- wherein (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 26.5 (w), 13.3 (vw), 12.1 (vw), 8.8 (m), 8.1 (w), 7.3 (w), 7.1 (w), 6.6 (w), 6.0 (w), 5.74 (vw), 5.60 (w), 5.27 (w), 4.96 (s), 4.81 (s), 4.57 (w), 4.41 (w), 4.35 (vw), 4.14 (s), 4.05 (vw), 3.81 (w), 3.74 (vw), 3.47 (w), 3.36 (w), 3.22 (vw), 3.15 (vw), 2.98 (w), 2.80 (vw), 2.75 (vw), 2.59 (vw),
- wherein (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 27.5 (w), 13.8 (vw), 9.3 (m), 8.6 (w), 8.1 (w), 7.4 (w), 7.1 (vw), 6.9 (s), 6.1 (w), 5.57 (vw), 5.19 (vw), 4.97 (vs), 4.75 (s), 4.62 (m), 4.13 (m), 4.04 (m), 3.97 (w), 3.82 (vw), 3.76 (vw), 3.66 (vw), 3.53 (w), 3.33 (w), 3.08 (w), 2.99 (vw),
- wherein (vs)=very strong intensity;
- (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
A crystalline polymorph of (3R,5S)- or (3S,5R)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å):
- 30.1 (w), 10.0 (w), 8.6 (w), 8.3 (w), 7.5 (s), 6.5 (w), 6.2 (vw), 6.0 (m), 5.01 (s), 4.83 (m), 4.31 (w), 4.13 (m), 3.95 (w), 3.54 (w), 3.44 (vw), 3.00 (w).
- wherein (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity;
- and (vw)=very weak intensity.
Dependencies are inferred from the claim text.